Today's Veterinary Practice

SEP-OCT 2015

Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.

Issue link: http://todaysveterinarypractice.epubxp.com/i/561362

Contents of this Issue

Navigation

Page 49 of 83

TOday'S VeTerinary PracTice | September/October 2015 | tvpjournal.com PracTicaL TecHniQUeS FrOM THe naVc inSTiTUTe Peer reviewed 48 Prevention of House Soiling While working to design the perfect litter box setup, it is important to clean any soiled areas and make them inaccessible or aversive, such as using plastic carpet runners with the "nubby" side up or aluminum foil, or setting up motion detectors. Medical Therapy anxiolytic medication is generally not indicated for feline inappropriate elimination. as stated earlier, if the cat has a urinary and/or intestinal condition, medical management should be administered as indicated by the therapeutic approach for that condition. WHEN THE CLIENT HAS HAD ENOUGH remember, by the time your client tells you about inappropriate elimination, his or her cat may have been urinating/defecating outside of the litter box for years, and the client may be looking for a quick fx. at that point, "thinking outside of the box" is paramount. Options to avoid relinquishment include: • allowing the cat to be an indoor/outdoor cat, or completely outdoor cat; there are enclosure and fencing options that make this possible • Boarding the cat at the clinic, giving the client time to implement the agreed upon treatment plan, such as cleaning soiled areas and purchasing new litter boxes. Ultimately, the goal is for the client to have no regrets: no regrets in keeping the cat and no regrets in rehoming the cat or euthanizing it. The best therapeutic plan ensures that both the client and the cat have good quality lives. References 1. carney Hc, Sadek TP, curtis TM, et al. aaFP and iSFM guidelines for diagnosing and solving house-soiling behavior in cats. J Feline Med Surg 2014; 16:579-598. 2. Borchelt PL, Voith VL. elimination behavior problems in cats. in Beaver BV (ed): Feline Behavior: A Guide for Veterinarians. Philadelphia: elsevier, 1992, p 204. 3. Borchelt PL. cat elimination behavior problems. Vet Clin North Am Small Anim Pract 1991; 21:257-264. 4. Schwartz S. Separation anxiety syndrome in cats: 136 cases (1991-2000). JAVMA 2012; 220:1028-1033. 5. Grigg eK, Pick L, nibblett B. Litter box preference in domestic cats: covered versus uncovered. J Feline Med Surg 2013; 15:280-284. t errY Marie C UrtiS Terry Marie Curtis, DVM, MS, Diplomate ACVB, teaches behavior courses at University of Florida College of Veterinary Medicine and also provides house call services in Florida and South Georgia. She was a panel contributor to the 2014 AAFP and ISFM Guidelines for Diagnosing and Solving House-Soiling Be - havior in Cats, and has worked with the Hemingway House Cats in Key West, Florida—an experience she described on ABC's Nightline in July of 2007. Dr. Curtis received her DVM from University of Florida and an MS in psychology at University of Georgia. She previously headed up the University of Florida Clinical Behavior Service. Read more about feline behavior at tvpjournal.com: • The 10 Commandments of Cat Management (May/June 2013) • Client Handout: How to enhance Your Pet's environment (July/August 2012) • Behavioral Medicine: Top 10 Tools for Success (July/August 2012) Caution Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Indications SENTINEL ® SPECTRUM ® (milbemycin oxime/lufenuron/praziquantel) is indicated for the prevention of heartworm disease caused by Diroflaria immitis; for the prevention and control of fea populations (Ctenocephalides felis); and for the treatment and control of adult roundworm (Toxocara canis, Toxascaris leonina), adult hookworm (Ancylostoma caninum), adult whipworm (Trichuris vulpis), and adult tapeworm (Taenia pisiformis, Echinococcus multilocularis and Echinococcus granulosus) infections in dogs and puppies two pounds of body weight or greater and six weeks of age and older. Dosage and Administration SENTINEL SPECTRUM should be administered orally, once every month, at the minimum dosage of 0.23 mg/lb (0.5 mg/kg) milbemycin oxime, 4.55 mg/lb (10 mg/kg) lufenuron, and 2.28 mg/lb (5 mg/kg) praziquantel. For heartworm prevention, give once monthly for at least 6 months after exposure to mosquitoes. Dosage Schedule Body Weight Milbemycin Oxime per chewable Lufenuron per chewable Praziquantel per chewable Number of chewables 2 to 8 lbs. 2.3 mg 46 mg 22.8 mg One 8.1 to 25 lbs. 5.75 mg 115 mg 57 mg One 25.1 to 50 lbs. 11.5 mg 230 mg 114 mg One 50.1 to 100 lbs. 23.0 mg 460 mg 228 mg One Over 100 lbs. Administer the appropriate combination of chewables To ensure adequate absorption, always administer SENTINEL SPECTRUM to dogs immediately after or in conjunction with a normal meal. SENTINEL SPECTRUM may be offered to the dog by hand or added to a small amount of dog food. The chewables should be administered in a manner that encourages the dog to chew, rather than to swallow without chewing. Chewables may be broken into pieces and fed to dogs that normally swallow treats whole. Care should be taken that the dog consumes the complete dose, and treated animals should be observed a few minutes after administration to ensure that no part of the dose is lost or rejected. If it is suspected that any of the dose has been lost, redosing is recommended. Contraindications There are no known contraindications to the use of SENTINEL SPECTRUM. Warnings Not for use in humans. Keep this and all drugs out of the reach of children. Precautions Treatment with fewer than 6 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. Prior to administration of SENTINEL SPECTRUM, dogs should be tested for existing heartworm infections. At the discretion of the veterinarian, infected dogs should be treated to remove adult heartworms. SENTINEL SPECTRUM is not effective against adult D. immitis. Mild, transient hypersensitivity reactions, such as labored breathing, vomiting, hypersalivation, and lethargy, have been noted in some dogs treated with milbemycin oxime carrying a high number of circulating microflariae. These reactions are presumably caused by release of protein from dead or dying microflariae. Do not use in puppies less than six weeks of age. Do not use in dogs or puppies less than two pounds of body weight. The safety of SENTINEL SPECTRUM has not been evaluated in dogs used for breeding or in lactating females. Studies have been performed with milbemycin oxime and lufenuron alone. Adverse Reactions The following adverse reactions have been reported in dogs after administration of milbemycin oxime, lufenuron, or praziquantel: vomiting, depression/lethargy, pruritus, urticaria, diarrhea, anorexia, skin congestion, ataxia, convulsions, salivation, and weakness. To report suspected adverse drug events, contact Virbac at 1-800-338-3659 or the FDA at 1-888-FDA-VETS. Information for Owner or Person Treating Animal Echinococcus multilocularis and Echinococcus granulosus are tapeworms found in wild canids and domestic dogs. E. multilocularis and E. granulosus can infect humans and cause serious disease (alveolar hydatid disease and hydatid disease, respectively). Owners of dogs living in areas where E. multilocularis or E. granulosus are endemic should be instructed on how to minimize their risk of exposure to these parasites, as well as their dog's risk of exposure. Although SENTINEL SPECTRUM was 100% effective in laboratory studies in dogs against E. multilocularis and E. granulosus, no studies have been conducted to show that the use of this product will decrease the incidence of alveolar hydatid disease or hydatid disease in humans. Because the prepatent period for E. multilocularis may be as short as 26 days, dogs treated at the labeled monthly intervals may become reinfected and shed eggs between treatments. Manufactured for: Virbac AH, Inc. P.O. Box 162059, Ft. Worth, TX 76161 NADA #141-333, Approved by FDA © 2015 Virbac Corporation. All Rights Reserved. SENTINEL and SPECTRUM are registered trademarks of Virbac Corporation. 02/15 TOday'S VeTerinary PracTice | September/October 2015

Articles in this issue

Links on this page

Archives of this issue

view archives of Today's Veterinary Practice - SEP-OCT 2015